Alivus Life Sciences Sales and Profits Analyzed
Alivus Life Sciences had a strong quarter, showing growth in both sales and profits. Specifically, sales increased by 4.84% to reach Rs 672.89 crore in the quarter ending December 2025. This is up from Rs 641.84 crore the previous quarter.
Key Points
- Sales jumped 4.84% to Rs 672.89 crore this quarter.
- Net profit increased by 9.71% to Rs 150.26 crore.
- Profit margins (OPM) improved slightly to 34.37%.
- Profit Before Tax (PBDT) rose by 22% to Rs 243.71 crore.
- Profit After Tax (PBT) increased by 21% to Rs 224.05 crore.
- Net Profit (NP) grew by 10% to Rs 150.26 crore.
Financial Performance Breakdown
The company’s net profit also went up, increasing by 9.71% to Rs 150.26 crore. This was higher than the previous quarter’s profit of Rs 136.96 crore. This indicates a positive trend in the company’s financial health.
Profit Margins
A key factor in the increased profits was a higher operating profit margin, or OPM. This improved to 34.37% compared to 29.65% the previous quarter. This shows efficient management of operating costs.
Profit Before Tax and After Tax
Profit Before Tax (PBDT) rose by 22% to Rs 243.71 crore. Similarly, Profit After Tax (PBT) climbed by 21% to Rs 224.05 crore, highlighting strong overall profitability.
Strong financial performance demonstrates Alivus Life Sciences’ strategic direction.



